# Zeng Zhiqiang

> Zeng Zhiqiang is a Series C investor at Huagai Capital backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Huagai Capital](https://shizune.co/investors/profile/huagai-capital)
- Location: Beijing, China
- Total investments: 4
- Last investment: Dec 2022
- Lead investor: 75%
- Last updated: Aug 2026

Zeng Zhiqiang is a managing director at Huagai Capital. Prior to this, he worked in Galaxy Securities, Boshi Fund, and served as president of Beijing Founder and Health Investment Co., Ltd., Managing Director of CITIC Industrial Fund. He engaged in the investment business for many years, in a secondary market investment has extensive experience.Zeng completed a bachelor's degree in Economics from Guanghua School of Management, Peking University, an MBA from Crummer School of Business, Rollins University, and an EMBA from Tsinghua University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 4 | 100% |
| Biotechnology | 2 | 50% |
| Pharmaceutical | 2 | 50% |
| Medical | 1 | 25% |
| Therapeutics | 1 | 25% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 3 | 75% |
| Series B | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Qitan Technology | Developer of a genome sequencing technology. The company takes advantage of nanopores to sequence single nucleic acid molecules.Using innovative nanopore gene sequencing technology, it provides single-molecule sequencing capability with long reading length, real-time output of sequencing results, low single-running cost, small and convenientinstrument, and cost-effective gene sequencing solution without complicated library preparation. It can directly detect the apparent modification of nucleic acids and expand the application of gene sequencing technology in cutting-edge biological research and clinical medicine such as instant diagnosis, metagenomics, epigenetics, RNA and transcriptomics. | $100.2M | Series C | Dec 23, 2022 |  |
| GenFleet Therapeutics | GenFleet Therapeutics is a developer and researcher of molecular pharmaceuticals targeting cancer treatments. The company specializes in developing innovative molecular-level pharmaceuticals and antibody drugs targeting various cancer systems, providing effective medical solutions to reactivate tumor-specific immune responses and to mobilize thebody's own immune system. | $78.7M | Series C | Dec 31, 2021 |  |
| Jinfang Pharmaceutical | Jinfang Pharmaceutical is focused on R&D and drug development from small molecule drug pipelines to diversified cutting-edge therapies. | $77.1M | Series C | Dec 31, 2021 |  |
| GeneQuantum Healthcare | GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech company that focuses on the research and development of innovative Bio-therapeutics.GeneQuantum was founded in August 2013 at Suzhou Industrial Park, and has built-up a world-class bio-conjugation technology platform, focusing on developing series of next generation anti-tumorAntibody-Drug-Conjugates (ADCs) with best-in-class potential. Securing this round of financing will significantly promote the development of current ADC candidates towards IND filling in both US and China, meanwhile further expanding the company's product pipeline. | $14.2M | Series B | May 07, 2019 |  |

4 of 4 investments shown.

## Co-investors
- [ABC International](https://shizune.co/investors/profile/abc-international) — VC Fund, 2 deals together
- [Baidu Ventures](https://shizune.co/investors/profile/baidu-ventures) — VC Fund, 2 deals together
- [CDH Investments](https://shizune.co/investors/profile/cdh-investments) — VC Fund, 2 deals together
- [Dyee Capital](https://shizune.co/investors/profile/dyee-capital) — VC Fund, 2 deals together
- [Huimei Capital](https://shizune.co/investors/profile/huimei-capital) — VC Fund, 2 deals together
- [Pan-Lin Capital](https://shizune.co/investors/profile/pan-lin-asset-management) — VC Fund, 2 deals together

## About Huagai Capital

VC Fund · Beijing, China

Huagai Capital is a private equity investment firm that invests in start-up or growth companies in the areas of healthcare, TMT, and culture.

5 contacts available at Huagai Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Lu Binghui | President & Co-Founder | https://shizune.co/investors/profile/lu-binghui |
| Meng Nan | Executive General Manager | https://shizune.co/investors/profile/meng-nan-d449 |
| Wang Shaokun | Vice President | https://shizune.co/investors/profile/wang-shaokun |
| Xiaolin Xu | Chairman & Co-founder | https://shizune.co/investors/profile/xiaolin-xu |
| Zeng Zhiqiang | Managing Partner | https://shizune.co/investors/profile/zeng-zhiqiang |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Zeng Zhiqiang invest in?

Zeng Zhiqiang invests primarily in Health Care, Biotechnology and Pharmaceutical startups, most often at Series C and Series B stage. Most of the 4 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Zeng Zhiqiang last invest?

The most recent investment recorded for Zeng Zhiqiang closed in Dec 2022. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co